Eight joint teams from Stony Brook University and Brookhaven National Laboratory have been awarded a total of $317,000 to support new research collaborations as part of the annual SBU-BNL Seed Grant Program. The SBU-BNL Seed Grant program now in its 23rd year is an annual competition fostering collaborative efforts between scientists at Stony Brook University and Brookhaven National Laboratory. Its mission is to provide key opportunities for developing synergistic activities that can grow research programs aligned with the strategic plans of both institutions. The program is an avenue to launch research that will advance investigators into a position to pursue new external funding. The subject of proposals can be any scientific topic that is of joint interest to SBU and BNL and should be innovative and exploratory and in line with the seeding character of the program. The awards are made using funds provided by Stony Brook University President Maurie McInnis ($250,000) and the
By
Sun Apr 18 2021
A possible explanation for why many cancer drugs that kill tumor cells in mouse models won’t work in human trials has been found.
A possible explanation for why many cancer drugs that kill tumor cells in mouse models won’t work in human trials has been found by researchers with The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics and McGovern Medical School.
The research was published today in Nature Communications.
In the study, investigators reported the extensive presence of mouse viruses in patient-derived xenografts (PDX). PDX models are developed by implanting human tumor tissues in immune-deficient mice, and are commonly used to help test and develop cancer drugs.
Research finds possible explanation for why many cancer drugs don t work in human trials
A possible explanation for why many cancer drugs that kill tumor cells in mouse models won t work in human trials has been found by researchers with The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics and McGovern Medical School.
The research was published today in
Nature Communications.
In the study, investigators reported the extensive presence of mouse viruses in patient-derived xenografts (PDX). PDX models are developed by implanting human tumor tissues in immune-deficient mice, and are commonly used to help test and develop cancer drugs.
Study on cancer drugs sanantoniopost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sanantoniopost.com Daily Mail and Mail on Sunday newspapers.